<DOC>
	<DOCNO>NCT00188812</DOCNO>
	<brief_summary>one year extension study follow previous double-blind study evaluate safety drug</brief_summary>
	<brief_title>Safety Donepezil Patients With Dementia Associated With Cerebrovascular Disease</brief_title>
	<detailed_description>A one year extension study patient complete E2020-A001-319 . Patients receive 5my donepezil daily first 8 week assess incidence advere event , change physical exam , ECG clinical lab determination . The result assess 6 timues year . After 8 week , investigator may increase dose 10mg/day patient patient show satisfactory tolerability . Six psychometric scale also evaluatd .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Cerebrovascular Disorders</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>must complete previous study E2020A001319 absence reliable caregiver clinically significant medical condition recent TIA</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>dementia</keyword>
	<keyword>stroke</keyword>
</DOC>